Nexavar India Purchasing Nexavar India Price Selling Nexavar India

Nexavar's price problem: Compared with Bayer's price, the price of Nexavar in India is only less than one-tenth of its price. So why is the company's Nexavar priced higher than this level? The reason is that the output of Nexavar is low and unstable, so it is hoarded by some people and raises its price. In fact, the price of Nexavar is relatively low in India, and its sales volume is not very large, so there are very few counterfeiters.
The difference between Nexavar in India and Nexavar in Germany
Bayer has the patent to invent Nexavar. Since its inception, Nexavar has been recommended by many institutions and patients because of its good efficacy. However, due to its high price, a The monthly dosage is around RMB 10, making many patients unable to afford such a high cost. Due to patent issues, two pharmaceutical companies in India have successfully copied Nexavar in their own country. Its efficacy and ingredients have also been recognized by the inspection agency and have been successfully launched on the market. The specifications of the company's Nexavar are different from those of: < br/> The company is the *3 tablet. The company is the * tablet
Nexavar, a new type of targeted product, has remarkable effects and has been promoted. The following is an analysis of its specific matters:
, Domestic Most of the products sold are Bayer's products, which are expensive. There is no doubt about this
The reason why they are expensive is because they exclusively own the patent rights. Bayer has invested a relatively large amount of preliminary research and development funds. The company operates for efficiency. Therefore, monopoly companies have pricing power
Regarding the issue of Nexavar in India:
The Nexavar imported by India is a product of an Indian pharmaceutical company and a copycat Bayer company, because India’s own patent laws allow this Such imitation is also to reduce costs in the country.
How effective is India? This is an issue that many people are concerned about and has doubts about. India's imitation technology has been recognized by the world, and its products also need to be tested, so its products have been recognized by many organizations and institutions. Make promotion.
How is it different from the company's products? In fact, there is no big difference between the two. It’s just that in terms of specifications, the content and ingredients are the same. The former is .? The dosage is large and the efficacy has a good reputation. Renal cell carcinoma is the most common type of kidney cancer, with more than 10,000 cases diagnosed and 10,000 deaths worldwide every year. A total of 10,000 patients with renal cell carcinoma participated in the trial, accounting for 10% of all patients with renal cell carcinoma. First-line treatment drugs targeting vascular endothelial growth factor receptor (R) are not very effective. Targeting R is the standard treatment for advanced disease and can be considered a very effective drug. But in many cases, tumor cells are able to evade drug attack, allowing the cancer to progress and develop resistance to the drug.
In second-line treatment, Nexavar is more effective than everolimus in patients with drug-resistant renal cancer. M.D., clinical director of the Genitourinary Cancer Treatment Center at Dana-Farber Cancer Institute, is the report's first author. He believes that current trials show that the drug is very promising in extending patients' lives better than standard kidney cancer treatments. He also mentioned that the drug has achieved breakthrough status by passing preliminary approval from the U.S. Food and Drug Administration and is likely to be available soon once final approval is obtained. Whether the drug can prolong overall survival and for how long requires more follow-up data to determine.
Nexavar is an oral small molecule tyrosine kinase inhibitor. In this phase III clinical trial, it was compared with everolimus as a second-line treatment for patients with advanced kidney cancer. The ultimate goal of the clinical trial is to determine progression-free survival, or how long the cancer remains in a state of arrested growth before it starts growing again. Median progression-free survival was 3.0 months with everolimus and .3 months with Nexavar. For patients treated with Nexavar, the proportion of tumor progression and patient death was lower than that with everolimus. Tumor size decreased in patients treated with Nexavar, but only in patients treated with everolimus.
Nexavar can target proteins related to the escape mechanism of cancer cells, such as tyrosine kinases and tyrosine kinases. Overall, the trial results show that Nexavar can reduce tumor size and slow tumor growth. In second-line treatment (where cancer cells have become drug-resistant), Nexavar is more effective than the current standard treatment (everolimus). The emergence and future launch of the drug Nexavar will undoubtedly bring good news to patients with complete kidney cancer.
A new drug has been found to be effective in patients with drug-resistant advanced kidney cancer, according to the results of a clinical trial at the Dana-Farber Cancer Institute in the United States. In this study, patients were receiving second-line treatment with everolimus, which halts tumor growth for a period of time. However, the effect of the new drug Nexavar is largely superior to that of everolimus. This study was published in the "New England Journal of Medicine" and the article believes that the new drug Nexavar may extend the survival of patients